Takeda secures $312 million zika vaccine development contract
September 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Takeda, US government, Zika, world health organization
Takeda has announced that it has been granted a $312 million contract from the US government to develop an inactivated, …
Clinton announces plan to tackle “unjustified price hikes”
September 5, 2016Sales and Marketing Drug pricing, Shkreli, US, clinton, generic drugs, president, price hikes
US Presidential candidate Hillary Clinton has outlined a wide-ranging set of proposals to tackle what she calls the “unjustified price …
GSK announce positive results for chronic obstructive pulmonary disease treatment
September 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing GlaxoSmithKline, Innoviva, Revlar Ellipta, chronic obstructive pulmonary disease
GlaxoSmithKline and its partner Innoviva have announced that its Relvar Ellipta achieved positive results in its COPD Salford lung study …
MSD drops osteoporosis trial drug due to stroke risk
September 5, 2016Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke
MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …
AZ’s first respiratory biologic meets primary endpoints in Phase III trials
September 5, 2016Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma
AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …
Top ten stories in the pharmaceutical industry this week
September 2, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile.com, top ten
As Mylan is left reeling from the backlash on its EpiPen price increase in the US, many lost their jobs …
FDA fast track designation for Biogen’s investigational Alzheimer’s treatment
September 2, 2016Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track
Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …
Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients
September 2, 2016Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia
Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …
NICE recommends Bayer’s Xofigo for prostate cancer treatment
September 2, 2016Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo
NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …
ABPI welcomes Roche back into the fold eight years after suspension
September 1, 2016Medical Communications, Research and Development ABPI, Roche, rejoin, suspension
Less than a decade after the company was suspended, Roche has now successfully re-joined the Association of the British Pharmaceutical …
Sepha is fast packing with a new EZ Blister upgrade.
September 1, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Packaging Equipment Specialist, Sepha, has released a functional upgrade for one of its original products, EZ Blister, the lab scale …
Cloud on the horizon: Cloud computing and the clinical trial
September 1, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, ICON, clinical trials, ibm
Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may just be the answer the …
Eli Lilly elects Jamere Jackson to board of directors
September 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, appointment
Eli Lilly has elected Jamere Jackson to its board of directors, effective 1 October, where he will serve on the …
Up to 120 jobs set to go as Novartis closes down Cell and Gene Therapies unit
September 1, 2016Manufacturing and Production, Research and Development CAR-T, Novartis, cart, cell and gene therapies
News has emerged that Novartis plans to close down its Cell and Gene Therapies unit, with up to 120 workers …
Lars Rebien Sørensen to retire as CEO of Novo Nordisk
September 1, 2016Novo Nordisk, appointment
Novo Nordisk has announced that its president and CEO Lars Rebian Sørensen (pictured) is to retire at the end of …
Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial
September 1, 2016Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq
Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …
Pfizer nabs EU approval for Xalkori for certain lung cancers
August 31, 2016Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer
The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …
Recipharm establishes long term supply agreement with Tillotts Pharma AG
August 31, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with …
The September issue of Pharmafocus is now live!
August 31, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo
The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …
AstraZeneca to pay £5.52 million to settle bribery probe
August 31, 2016Research and Development AstraZeneca, SEC, misconduct
According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
